×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TRVI – trevi therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TRVI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
07:39 am
trvi
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
11/21
07:30 am
trvi
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Low
Report
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
11/8
08:46 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
11/7
02:31 am
trvi
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]
11/6
04:05 pm
trvi
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/30
04:05 pm
trvi
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Medium
Report
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
10/22
08:32 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/21
07:30 am
trvi
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Medium
Report
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:52 pm
trvi
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Venrock Healthcare Capital Partners II, L.P.
Medium
Report
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Venrock Healthcare Capital Partners II, L.P.
11/13
04:31 pm
trvi
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Rubric Capital Management LP
Low
Report
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Rubric Capital Management LP
11/8
06:58 pm
trvi
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
Low
Report
Form SC 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
11/6
04:21 pm
trvi
Form 10-Q Trevi Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q Trevi Therapeutics, Inc. For: Sep 30
11/6
04:13 pm
trvi
Form 8-K Trevi Therapeutics, Inc. For: Nov 06
Medium
Report
Form 8-K Trevi Therapeutics, Inc. For: Nov 06
11/6
10:30 am
trvi
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
Low
Report
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
10/23
02:44 pm
trvi
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Rosalind Advisors, Inc.
Low
Report
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: Rosalind Advisors, Inc.
10/21
10:44 am
trvi
Form 8-K Trevi Therapeutics, Inc. For: Oct 21
Low
Report
Form 8-K Trevi Therapeutics, Inc. For: Oct 21
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/31
Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock.
67.9%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
3/16 TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE 48.3%
6/18 Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference 12.7%
5/13 Form 3 Trevi Therapeutics, Inc. For: May 07 Filed by: OSHEA WILLIAM J 11.5%
3/16 Trevi Therapeutics up 57% on advancement of key programs [Seeking Alpha] 10.3%
4/13 Form 4 Trevi Therapeutics, Inc. For: Apr 03 Filed by: Behbahani Ali 9.9%
2/25 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 8.6%
1/15 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.9%
11/14 Form 8-K Trevi Therapeutics, Inc. For: Nov 14 7.9%
8/21 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 7.6%
TOP News Decliners
5/7
Form S-1/A Trevi Therapeutics, Inc.
-16.9%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
10/10 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -9.8%
3/11 Trevi Therapeutics Inc (NASDAQ: TRVI) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.8%
8/12 Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments -7.1%
1/31 Form SC 13G Trevi Therapeutics, Inc. Filed by: Lundbeckfond Invest A/S -6.2%
2/13 Form SC 13G Trevi Therapeutics, Inc. Filed by: TPG Group Holdings (SBS) Advisors, Inc. -6.2%
9/19 Trevi Therapeutics Inc (NASDAQ: TRVI) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.9%
2/20 Trevi Therapeutics to Present at SVB Leerink Healthcare Conference -4.0%
7/2 Form 8-K Trevi Therapeutics, Inc. For: Jun 28 -4.0%
6/25 Trevi Therapeutics (TRVI) Investor Presentation - Slideshow [Seeking Alpha] -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: